JP2005527599A5 - - Google Patents

Download PDF

Info

Publication number
JP2005527599A5
JP2005527599A5 JP2004500866A JP2004500866A JP2005527599A5 JP 2005527599 A5 JP2005527599 A5 JP 2005527599A5 JP 2004500866 A JP2004500866 A JP 2004500866A JP 2004500866 A JP2004500866 A JP 2004500866A JP 2005527599 A5 JP2005527599 A5 JP 2005527599A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
administered
zonisamide
alkali metal
metal salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2004500866A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005527599A (ja
Filing date
Publication date
Priority claimed from US10/429,474 external-priority patent/US20040029941A1/en
Application filed filed Critical
Publication of JP2005527599A publication Critical patent/JP2005527599A/ja
Publication of JP2005527599A5 publication Critical patent/JP2005527599A5/ja
Withdrawn legal-status Critical Current

Links

JP2004500866A 2002-05-06 2003-05-05 肥満および摂食障害におけるゾニサミドの使用 Withdrawn JP2005527599A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37844602P 2002-05-06 2002-05-06
US10/429,474 US20040029941A1 (en) 2002-05-06 2003-05-02 Zonisamide use in obesity and eating disorders
PCT/US2003/014459 WO2003092682A1 (en) 2002-05-06 2003-05-05 Zonisamide use in obesity and eating disorders

Publications (2)

Publication Number Publication Date
JP2005527599A JP2005527599A (ja) 2005-09-15
JP2005527599A5 true JP2005527599A5 (https=) 2006-09-14

Family

ID=29406837

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004500866A Withdrawn JP2005527599A (ja) 2002-05-06 2003-05-05 肥満および摂食障害におけるゾニサミドの使用

Country Status (5)

Country Link
US (2) US20040029941A1 (https=)
EP (1) EP1503755A1 (https=)
JP (1) JP2005527599A (https=)
AU (1) AU2003228933A1 (https=)
WO (1) WO2003092682A1 (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3173082A1 (en) * 2002-05-17 2017-05-31 Duke University Method for treating obesity
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
US20050059718A1 (en) * 2003-02-21 2005-03-17 Hayato Miyachi Methods of using zonisamide as an adjunctive therapy for partial seizures
EP1617832B1 (en) 2003-04-29 2008-03-12 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
US20050043773A1 (en) * 2003-08-21 2005-02-24 Ivan Lieberburg Methods of improving the safety of zonisamide therapy
US20050043704A1 (en) * 2003-08-21 2005-02-24 Eisai Co., Ltd Methods of using zonisamide as an adjunctive therapy for partial seizures
US20050043705A1 (en) * 2003-08-21 2005-02-24 Eisai Co., Ltd. Methods of using zonisamide as an adjunctive therapy for partial seizures
US20050154033A1 (en) * 2004-01-08 2005-07-14 Eisai Co., Ltd Methods of using zonisamide as an adjunctive therapy for partial seizures
US20050154034A1 (en) * 2004-01-08 2005-07-14 Eisai Co., Ltd. Methods of using zonisamide as an adjunctive therapy for partial seizures
US20050154032A1 (en) * 2004-01-08 2005-07-14 Eisai Co., Ltd Methods of using zonisamide as an adjunctive therapy for partial seizures
US20050154036A1 (en) * 2004-01-09 2005-07-14 Eisai Co., Ltd. Methods of using zonisamide as an adjunctive therapy for partial seizures
US20050154035A1 (en) * 2004-01-09 2005-07-14 Eisai Co., Ltd. Methods of using zonisamide as an adjunctive therapy for partial seizures
US20050154037A1 (en) * 2004-01-09 2005-07-14 Eisai Co., Ltd. Methods of using zonisamide as an adjunctive therapy for partial seizures
KR20060128995A (ko) * 2004-01-13 2006-12-14 듀크 유니버시티 체중감량에 영향을 미치는 항경련제와 항정신병 약물의조성물
US7713959B2 (en) * 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
US20060160750A1 (en) * 2004-01-13 2006-07-20 Krishnan K R R Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss
US20060100205A1 (en) * 2004-04-21 2006-05-11 Eckard Weber Compositions for affecting weight loss
CA2565154A1 (en) * 2004-05-03 2005-11-24 Duke University Compositions for affecting weight loss
WO2005113069A2 (en) * 2004-05-14 2005-12-01 Research Development Foundation Use of circumin and analogues as inhibitors of acc2
WO2006133045A1 (en) * 2005-06-03 2006-12-14 Elan Pharma International, Limited Nanoparticulate benidipine compositions
CN101370488B (zh) 2005-11-22 2012-07-18 奥雷西根治疗公司 增加胰岛素敏感性的组合物
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
DK2089005T3 (da) 2006-11-09 2010-07-19 Orexigen Therapeutics Inc Lagdelte farmaceutiske formuleringer omfattende et hurtigt opløsende mellemlag
KR20170077291A (ko) 2006-11-09 2017-07-05 오렉시젠 세러퓨틱스 인크. 단위 용량 팩키지
WO2009158114A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
MX344303B (es) 2010-01-11 2016-12-13 Orexigen Therapeutics Inc Metodos para proveer terapia de perdida de peso en pacientes con depresion mayor.
CN110893181A (zh) 2012-06-06 2020-03-20 纳丙药业有限责任公司 治疗超重和肥胖症的方法
CA2917702A1 (en) 2013-07-18 2015-01-22 Jazz Pharmaceuticals International Iii Limited Treatment for obesity
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations
CA3016810C (en) 2016-03-07 2024-04-02 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Compositions and methods for administering ppar.gamma. agonists, surfactant peptides and phospholipids
CN111565707A (zh) 2017-06-14 2020-08-21 森玛治疗公司 用于递送治疗物的装置和方法
EP3668508A1 (en) 2017-08-19 2020-06-24 FTF Pharma Private Limited An oral pharmaceutical composition comprising zonisamide and process of preparation thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US25038A (en) * 1859-08-09 Egg-beater or churn
US33965A (en) * 1861-12-17 Improvement in rifle-sights
US4172896A (en) * 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
US4513006A (en) * 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
US5719197A (en) * 1988-03-04 1998-02-17 Noven Pharmaceuticals, Inc. Compositions and methods for topical administration of pharmaceutically active agents
US5853975A (en) * 1994-08-23 1998-12-29 Millennium Pharmaceuticals, Inc. Methods for identifying compositions for the treatment of body weight disorders, including obesity
US5576321A (en) * 1995-01-17 1996-11-19 Eli Lilly And Company Compounds having effects on serotonin-related systems
AP1285A (en) * 1996-06-28 2004-06-24 Ortho Mcneil Pharm Inc Anticonvulsant sulfamate derivatives useful in treating obesity.
US6262049B1 (en) * 1997-10-28 2001-07-17 Schering Corporation Method of reducing nicotine and tobacco craving in mammals
CN100548290C (zh) * 1999-02-24 2009-10-14 辛辛那提大学 氨基磺酸酯衍生物用于治疗冲动控制障碍的用途
MXPA01009893A (es) * 1999-04-01 2003-07-28 Esperion Therapeutics Inc Compuestos con eter, composiciones y usos de estos.
US6403657B1 (en) * 1999-10-04 2002-06-11 Martin C. Hinz Comprehensive pharmacologic therapy for treatment of obesity
US6437147B1 (en) * 2000-03-17 2002-08-20 Novo Nordisk Imidazole compounds
US6555519B2 (en) * 2000-03-30 2003-04-29 Bristol-Myers Squibb Company O-glucosylated benzamide SGLT2 inhibitors and method
US6191117B1 (en) * 2000-07-10 2001-02-20 Walter E. Kozachuk Methods of producing weight loss and treatment of obesity
EP3173082A1 (en) * 2002-05-17 2017-05-31 Duke University Method for treating obesity
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
KR20060128995A (ko) * 2004-01-13 2006-12-14 듀크 유니버시티 체중감량에 영향을 미치는 항경련제와 항정신병 약물의조성물

Similar Documents

Publication Publication Date Title
JP2005527599A5 (https=)
JP2005537268A5 (https=)
JP2006523216A5 (https=)
JP2002522485A5 (https=)
PT1173178E (pt) Composicao compreendendo apomorfina e sildenafil e utilizacao da mesma para o tratamento da disfuncao erectil
JP2021512121A5 (https=)
NZ527113A (en) Rapid-onset medicament for the treatment of sexual dysfunction
JP2004519469A5 (https=)
JP2006503850A5 (https=)
JP2005515966A5 (https=)
JP2006515351A5 (https=)
JP2023116697A5 (https=)
JP2009506054A5 (https=)
JP2001518509A5 (https=)
WO2004045593A3 (en) Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy
JP2009515901A5 (https=)
JP2004537500A5 (https=)
CN110755432A (zh) 烟酰胺在制备治疗手足皮肤反应制剂中的应用
JP2008516909A5 (https=)
JP2005513105A5 (https=)
Smith et al. Evaluation of topotecan in patients with recurrent for metastatic squamous cell carcinoma of the head and neck: A phase II Southwest Oncology Group study
JPH0455172B2 (https=)
JPWO2022234457A5 (https=)
JPS62426A (ja) 新生物疾患の治療方法
Botea Analgesics